Last reviewed · How we verify
NCT04154826: IMPULSE-7
Recombinant Interleukin-7 (CYT107) to Treat Patients With Refractory Nontuberculous Mycobacterial Lung Disease
Phase 2 trial testing Recombinant human interleukin-7 in Mycobacterium Infections, Nontuberculous in 8 participants. Terminated before completion.
31 December 2023
Quick facts
| Lead sponsor | Revimmune |
|---|---|
| Phase | Phase 2 |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 8 |
| Start date | 30 November 2020 |
| Primary completion | 31 December 2023 |
| Estimated completion | 30 March 2024 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Recombinant human interleukin-7 — full drug profile →
Conditions studied
- Mycobacterium Infections, Nontuberculous — all drugs for Mycobacterium Infections, Nontuberculous →
Sponsor
Revimmune — full company profile →
Who can join
Adults 18 to 85, any sex, with Mycobacterium Infections, Nontuberculous. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A prospective, single-center, single-blinded study involving patients with refractory nontuberculous mycobacteria lung disease to ascertain pharmacokinetics, safety, efficacy, and tolerability of two dose levels of parenteral administration of recombinant Interleukin-7 (IL-7) (CYT107).
Publications & conference data
5 peer-reviewed publications reference this trial (live from Europe PMC):
-
Analysis of the Clinical Pipeline of Treatments for Drug-Resistant Bacterial Infections: Despite Progress, More Action Is Needed.
Butler MS, Gigante V, Sati H, Paulin S, et al · · 2022 · cited 165× · PMID 35007139 · DOI 10.1128/aac.01991-21 -
Engineering cytokine therapeutics.
Deckers J, Anbergen T, Hokke AM, de Dreu A, et al · · 2023 · cited 132× · PMID 37064653 · DOI 10.1038/s44222-023-00030-y -
Beyond antibiotics: recent developments in the diagnosis and management of nontuberculous mycobacterial infection.
Gleeson LE, Waterer G. · · 2022 · cited 9× · PMID 36337137 · DOI 10.1183/20734735.0171-2021 -
Recombinant interleukin-7 treatment of refractory <i>Mycobacterium avium</i> complex lung disease (IMPULSE-7): a pilot phase II, single-center, randomized, clinical trial.
Mejia-Chew C, Spec A, Walton AH, Ulezko Antonova A, et al · · 2025 · cited 2× · PMID 40351870 · DOI 10.1177/20499361251339300 -
Review of the Canadian Nontuberculous Mycobacterial Disease Landscape-Challenges and Opportunities.
Vahid S, Yan M, Turvey SL. · · 2025 · PMID 41441567 · DOI 10.3390/tropicalmed10120328
Verify or expand the search:
- PubMed search for NCT04154826
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Revimmune trials
Trials by the same sponsor.
- NCT04927169 — InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection (Brazil Cohort) · Phase 2 · terminated
- NCT04426201 — InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic Patients With COVID-19 Infection ( ILIAD-7-US-O ) · Phase 2 · terminated
- NCT04442178 — InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection ( ILIAD-7-US-I ) · Phase 2 · terminated
- NCT04407689 — InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection FR BL Cohort · Phase 2 · terminated
- NCT04379076 — InterLeukin-7 (CYT107) to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection UK Cohort · Phase 2 · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04154826 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Revimmune
- Last refreshed: 11 April 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04154826.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing